ClinicalTrials.gg
Active, not recruitingNCT07516418Updated Nov 13, 2026

Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age

A Phase 1 interventional study of H5 Flu Investigational Medical Product (IMP) 1 and H5 Flu IMP 2 in Respiratory Syncytial Virus (RSV) and Influenza A(H5N1), sponsored by Sanofi. Active, not recruiting at 6 sites in Australia. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Sanofi · Phase 1, Interventional, and Prevention

Updated Nov 13, 2026Now Active, not recruitingEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Respiratory Syncytial Virus Infections by Sanofi — none open to participants now, 2 under way, none of them phase 3. Respiratory Syncytial Virus Infections · Sanofi.

Enrollment
7th of 14
360 · median 310
Started
2026
the only one that year
Phase 1
8 of 15
none open now
Registered
15th of 15
by date

Among the 15 studies in Respiratory Syncytial Virus Infections by Sanofi, this one is the 7th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2026, is one of 8 in phase 1, and was the 15th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

None of the 15 studies in Respiratory Syncytial Virus Infections by Sanofi is open now. The open studies under Respiratory Syncytial Virus Infections, anywhere →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 49 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Respiratory Syncytial Virus Infections by Sanofi as a file.
02

Study summary

The purpose of this study is to evaluate the safety and immunogenicity of different formulations of vaccines encoding the RSV monovalent antigen or the Flu hemagglutinin subtype 5 (H5) antigen in healthy participants aged 18 to 49 years.

The total duration of study participation for each participant varies by stage and treatment arm.

Stage 1:

  • For Arm 1, Arm 2, and Arm 3 the duration of study participation will be approximately 7 months for each participant.
  • For Arm 4, Arm 5, and Arm 6 the duration of study participation will be approximately 6 months for each participant.

Stage 2: For all arms, the duration of study participation will be approximately 7 months for each participant.

03

Conditions studied

  • Respiratory Syncytial Virus (RSV)
  • Influenza A(H5N1)

Keywords

  • RSV
  • RSV Infection
  • RSV Vaccine
  • Flu
  • Flu Infection
  • Flu Vaccine
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 49 years on the day of inclusion
  • A female participant is eligible to participate if she is not pregnant or breastfeeding and of the following conditions applies:
  • Is of NCBP (Non-). To be considered of NCBP, a female must be for at least 1 year, or surgically sterile. OR
  • Is of CBP (Child-Bearing Potential) and uses an effective method or abstinence from at least 4 weeks prior to study intervention administration until at least 12 weeks after the last study intervention administration.

Exclusion criteria

Exclusion Criteria:

  • Any condition which, in the opinion of the Investigator, might interfere with the evaluation of the study objectives

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
360 participants (actual)

Study arms

  • Experimental
    Stage 1, Arm 1

    Participants will receive a single IM (Intramuscular) injection on day 1 and day 22 of the H5 Flu vaccines according to their randomization schedule.

    Biological: H5 Flu Investigational Medical Product (IMP) 1

  • Experimental
    Stage 1, Arm 2

    Participants will receive a single IM (Intramuscular) injection on day 1 and day 22 of the H5 Flu vaccines according to their randomization schedule.

    Biological: H5 Flu IMP 2

  • Experimental
    Stage 1, Arm 3

    Participants will receive a single IM (Intramuscular) injection on day 1 and day 22 of the H5 Flu vaccines according to their randomization schedule.

    Biological: H5 Flu IMP 3

  • Experimental
    Stage 1, Arm 4

    Participants will receive a single IM (Intramuscular) injection on day 1 of the RSV vaccines according to their randomization schedule.

    Biological: RSV IMP 4

  • Experimental
    Stage 1, Arm 5

    Participants will receive a single IM (Intramuscular) injection on day 1 of the RSV vaccines according to their randomization schedule.

    Biological: RSV IMP 5

  • Experimental
    Stage 1, Arm 6

    Participants will receive a single IM (Intramuscular) injection on day 1 of the RSV vaccines according to their randomization schedule.

    Biological: RSV IMP 6

  • Experimental
    Stage 2, Arm 1

    Participants will receive a single IM (Intramuscular) injection on day 1 and day 22 of the H5 Flu vaccines according to their randomization schedule.

    Biological: H5 Flu IMP 7

  • Experimental
    Stage 2, Arm 2

    Participants will receive a single IM (Intramuscular) injection on day 1 and day 22 of the H5 Flu vaccines according to their randomization schedule.

    Biological: H5 Flu IMP 8

  • Experimental
    Stage 2, Arm 3

    Participants will receive a single IM (Intramuscular) injection on day 1 and day 22 of the H5 Flu vaccines according to their randomization schedule.

    Biological: H5 Flu IMP 9

  • Experimental
    Stage 2, Arm 4

    Participants will receive a single IM (Intramuscular) injection on day 1 and day 22 of the H5 Flu vaccines according to their randomization schedule.

    Biological: H5 Flu IMP 10

  • Experimental
    Stage 2, Arm 5

    Participants will receive a single IM (Intramuscular) injection on day 1 and day 22 of the H5 Flu vaccines according to their randomization schedule.

    Biological: H5 Flu IMP 11

  • Experimental
    Stage 2, Arm 6

    Participants will receive a single IM (Intramuscular) injection on day 1 and day 22 of the H5 Flu vaccines according to their randomization schedule.

    Biological: H5 Flu IMP 12

Interventions

  • Suspension for injection. Route of administration: Intramuscular (IM) injection

  • BiologicalH5 Flu IMP 2

    Suspension for injection. Route of administration: Intramuscular (IM) injection

  • BiologicalH5 Flu IMP 3

    Suspension for injection. Route of administration: Intramuscular (IM) injection

  • BiologicalRSV IMP 4

    Suspension for injection. Route of administration: Intramuscular (IM) injection

  • BiologicalRSV IMP 5

    Suspension for injection. Route of administration: Intramuscular (IM) injection

  • BiologicalRSV IMP 6

    Suspension for injection. Route of administration: Intramuscular (IM) injection

  • BiologicalH5 Flu IMP 7

    Suspension for injection. Route of administration: Intramuscular (IM) injection

  • BiologicalH5 Flu IMP 8

    Suspension for injection. Route of administration: Intramuscular (IM) injection

  • BiologicalH5 Flu IMP 9

    Suspension for injection. Route of administration: Intramuscular (IM) injection

  • BiologicalH5 Flu IMP 10

    Suspension for injection. Route of administration: Intramuscular (IM) injection

  • BiologicalH5 Flu IMP 11

    Suspension for injection. Route of administration: Intramuscular (IM) injection

  • BiologicalH5 Flu IMP 12

    Suspension for injection. Route of administration: Intramuscular (IM) injection

06

What researchers measure

Primary outcomes

  1. Presence of any unsolicited systemic Adverse Events (AEs) reported within 30 minutes after vaccination

    Time frame: On Day 1

  2. Presence of solicited injection site reactions (ie, injection site pain, injection site erythema, injection site swelling, pre-listed in participant's diary and in the eCRF (electronic case report form)) occurring through 7 days after each vaccination

    Time frame: Day 1 through day 8

  3. Presence of solicited systemic reactions (ie, fever, headache, and only new or worsened fatigue, myalgia, arthralgia, and chills pre-listed in the participant's diary and in the eCRF) occurring through 7 days after each vaccination

    Time frame: Day 1 through day 8

  4. Presence of unsolicited AEs reported through 20 days after the first vaccination and after the second vaccination for IMPs with the Flu H5 antigen

    Time frame: Day 1 through day 21

  5. Presence of unsolicited AEs reported through 28 days after vaccination for IMPs with the RSV antigen

    Time frame: Day 1 through day 29

  6. Presence of SAEs (Serious Adverse Events) and AESIs (Adverse Events of Special Interest) throughout the study (ie, through 6 months after vaccination)

    Time frame: SAE: Screening day through day 202 (IMPs containing Flu H5 antigen), Screening day through day 181 (IMPs containing RSV antigen); AESI: Day 1 through day 202 (IMPs containing Flu H5 antigen), Day 1 through day 181 (IMPs containing RSV antigen)

  7. Presence of out-of-range biological test results (including shift from baseline values) through 7 days after each vaccination

    Time frame: Screening through day 8

  8. Presence of AEs leading to study discontinuation throughout the study (ie, through 6 months after vaccination)

    Time frame: Screening through day 202 (IMPs containing Flu H5 antigen), Screening through day 181 (IMPs containing RSV antigen)

  9. RSV A and RSV B serum nAb (neutralizing antibodies) titers at pre-vaccination and 28 days post-vaccination in all participants receiving IMPs with the RSV antigen

    Time frame: Day 1 and day 29

  10. Flu H5 antibody (Ab) titer measured by hemagglutination inhibition (HAI) at pre-vaccination and 21 and 42 days post-vaccination in all participants receiving IMPs with the Flu H5 antigen

    Time frame: Day 1, day 22 and day 43

  11. Hemagglutination Inhibition (HAI) geometric mean titer ratio at 21 and 42 days post-vaccination relative to pre-vaccination for all participants receiving IMPs with the Flu H5 antigen

    Ratio of post-vaccination to pre-vaccination hemagglutination inhibition (HAI) antibody titers, calculated as Day 22/Day 1 and Day 43/Day 1.

    Time frame: Day 1, day 22 and day 43

  12. Seroconversion rate based on Hemagglutination inhibition (HAI) antibody titers at pre-vaccination and 21 and 42 days post-vaccination in all participants receiving IMPs with the Flu H5 antigen

    Time frame: Day 1, day 22 and day 43

  13. Proportion of participants with Hemagglutination Inhibition (HAI) antibody titer ≥40 at pre-vaccination and 21 and 42 days post-vaccination in all participants receiving IMPs with the Flu H5 antigen

    Time frame: Day 1, day 22, and day 43

  14. Proportion of participants with detectable HAI antibody titer ≥10 at pre-vaccination and 21 and 42 days post-vaccination in all participants receiving IMPs with the Flu H5 antigen

    Time frame: Day 1, day 22, and day 43

Secondary outcomes

  1. Geometric mean neutralizing antibody titers measured by Neutralization Assay (NT) at pre-vaccination and 21 and 42 days post-vaccination in all participants receiving IMPs with the Flu H5 antigen

    Time frame: Day 1, day 22, and day 43

  2. Neutralizing antibody titer ratio at pre-vaccination and 21 and 42 days post-vaccination in all participants receiving IMPs with the Flu H5 antigen

    Ratio of post-vaccination to pre-vaccination neutralizing antibody titers, calculated as Day 22/Day 1 and Day 43/Day 1 using a validated neutralization (NT) assay.

    Time frame: Day 1, day 22, and day 43

  3. Proportion of participants with neutralizing antibody titers ≥20, ≥40, and ≥80 at pre-vaccination and 21 and 42 days post-vaccination in all participants receiving IMPs with the Flu H5 antigen

    Time frame: Day 1, day 22, and day 43

  4. Proportion of participants with detectable neutralizing antibody titers ≥10 at pre-vaccination and 21 and 42 days post-vaccination in all participants receiving IMPs with the Flu H5 antigen

    Time frame: Day 1, day 22, and day 43

  5. Proportion of participants with ≥2-fold and ≥4-fold increase in neutralizing antibody titers at pre-vaccination and 21 and 42 days post-vaccination in all participants receiving IMPs with the Flu H5 antigen

    Time frame: Day 1, day 22, and day 43

07

Study locations

6 sites
  • Site # 0361002
    Griffith, Queensland 4222, Australia
  • Site # 0361001
    Herston, Queensland 4006, Australia
  • Site # 0361003
    Morayfield, Queensland 4506, Australia
  • Site # 0361005
    Sippy Downs, Queensland 4556, Australia
  • Site # 03610004
    South Brisbane, Queensland 4104, Australia
  • Site # 036006
    Taringa, Queensland 4068, Australia
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Supporting information: Study protocol, Statistical analysis plan

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2027, 11 months after the start.

Of 44 industry-sponsored phase 1 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's planned 11 months is above that.

Counting every sponsor, half of 57 studies reached it within 8 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2026
First posted
Apr 8, 2026
StartActual
Apr 15, 2026
Primary completionEst.
Apr 4, 2027
CompletionEst.
Apr 4, 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 13, 2026
Enrollment
570 (estimated)→360 (actual)
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Recruiting→Active, not recruiting
    Enrollment 570 (estimated)→360 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07516418
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Apr 8, 2026
Start date
Apr 15, 2026
Primary completion
Apr 4, 2027 (estimated)
Completion
Apr 4, 2027 (estimated)
Last update
Nov 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inosine Monophosphate

Start the discussion